clinical trial risk

Clinical trials that fail, get delayed or need more studies, holding up a drug or device.

Exposure · 25 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ADRX ADARx Pharmaceuticals, Inc.

    Exposed“Trials may be delayed, suspended or terminated because of safety signals, regulatory requests, manufacturing or protocol issues, limited enrollment, or CRO and site performance.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • APMD Apnimed, Inc.

    Exposed“The company also cautions that trial results are preliminary and may not be replicated.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ARMP Armata Pharmaceuticals, Inc.

    Exposed“Trials may be delayed, enroll slowly, fail to complete, or require additional studies, increasing costs and postponing approval and revenue.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • ASPE Aspen Neuroscience, Inc.

    Exposed“The approach is novel, and its safety, efficacy, ability to slow or halt PD progression, and regulatory prospects are unproven.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • ATTO Attovia Therapeutics, Inc.

    Exposed“Drug development is lengthy, costly and uncertain, and early findings may not predict later results.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BBTX Bambusa Therapeutics, Inc.

    Exposed“Development is lengthy, costly and uncertain.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • BLSM BlossomHill Therapeutics, Inc.

    Exposed“Development is lengthy, costly, and uncertain: encouraging preclinical or early clinical results may not predict later outcomes, and delays, additional studies, trial changes, manufacturing issues, or regulatory disagreement could increase costs and allow competitors to advance first.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BRVE Braveheart Bio, Inc.

    Exposed“Trials can be delayed by enrollment and retention problems, dropouts, site or contractor performance, supply constraints, or additional regulatory requirements; negative or inconclusive results could prevent approval or restrict the indication or label.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • CAPR CAPRICOR THERAPEUTICS, INC.

    Exposed“The FDA issued a Complete Response Letter in July 2025, citing insufficient substantial evidence of effectiveness and requesting additional clinical data.”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • CTY CITY THERAPEUTICS, INC.

    Exposed“Early safety, knockdown or preclinical findings may not predict later results.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • EMI Encore Medical, Inc.

    Exposed“Enrollment or trial delays, unfavorable results, or failure to obtain approval could prevent or delay U.S. commercialization.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

  • ETRA Electra Therapeutics, Inc.

    Exposed“Ipsoprubart’s SURPASS trial is single-arm and open-label, studying treatment-naïve adults and children with sHLH.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • IAM Iambic Therapeutics, Inc.

    Exposed“IAM has not demonstrated that it can obtain drug approval, and trials may be delayed, suspended or fail because of safety or efficacy results, recruitment and retention problems, regulatory or ethics review, CRO or site performance, inadequate funding, or manufacturing and supply issues.”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • LTGO Latigo Biotherapeutics, Inc.

    Exposed“Trial enrollment, CRO and site performance, data quality, safety findings, manufacturing availability, and regulatory review could delay or prevent approval.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issuePre-revenue ·

    Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

  • LYCA Lycia Therapeutics, Inc.

    Exposed“Clinical success depends on showing efficacy and acceptable safety, recruiting and retaining participants, completing trials on time, obtaining regulatory clearance, and securing funding, IP protection, manufacturing, reimbursement and market acceptance.”

    Latest 424B4final IPO prospectusMixedPre-revenue ·

    Develops protein degraders for food allergy and Graves’ disease; raises $318M gross to advance clinical trials.

  • NUOX NuvOx Therapeutics, Inc.

    Exposed“Trials may fail, reveal new safety issues, enroll slowly or require additional studies.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • PFE Pfizer

    Exposed“Development is lengthy, costly and failure-prone: candidates may miss milestones, require additional trials, fail approval, receive restrictive labeling or prove less competitive than expected.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • REGN Regeneron Pharmaceuticals

    Exposed“Clinical development is costly and uncertain: trials may fail to establish safety or efficacy, enroll adequately, or meet changing regulatory expectations.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%
  • RZRA Rezera Inc.

    Exposed“Clinical development is lengthy, expensive and uncertain.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SCTX Scribe Therapeutics, Inc.

    Exposed“Safety and efficacy are uncertain, including risks of unintended on- or off-target effects, inadequate efficacy, immune responses and LNP-related liver toxicity.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • SDGR Schrödinger, Inc.

    Exposed“Trial enrollment, safety, results, regulatory review, manufacturing, and commercial acceptance are uncertain;”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • STA Starton Holdings, Inc.

    Exposed“Clinical development is lengthy, costly and uncertain.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • VOGX Vogenx, Inc.

    Exposed“Trials may be delayed, inconclusive, or unsuccessful because of safety or efficacy findings, regulatory decisions, enrollment or retention difficulties, limited clinical-site capacity, contractor performance, manufacturing constraints, or inadequate funding.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • VRTX Vertex Pharmaceuticals

    Exposed“More broadly, the success of Vertex’s clinical and preclinical programs, regulatory filings, development timelines, and research and development investments remains uncertain.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%
  • WWB WINDWARD BIO GROUP AG

    Exposed“Trials may fail efficacy or safety endpoints, reveal adverse events, enroll slowly, or require additional studies.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback